These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 28828933)

  • 1. Impact of Timely Treatment Intensification on Glycemic Goal Achievement in Patients With Type 2 Diabetes Failing Metformin Monotherapy.
    Mahabaleshwarkar R; Templin M; Gohs F; Mulder H; DeSantis A; Ejzykowicz F; Rajpathak S; Wilkins N
    Diabetes Educ; 2017 Oct; 43(5):495-505. PubMed ID: 28828933
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of time to treatment intensification on glycemic goal attainment among patients with type 2 diabetes failing metformin monotherapy.
    Rajpathak SN; Rajgopalan S; Engel SS
    J Diabetes Complications; 2014; 28(6):831-5. PubMed ID: 25104238
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intensification of Diabetes Therapy and Time Until A1C Goal Attainment Among Patients With Newly Diagnosed Type 2 Diabetes Who Fail Metformin Monotherapy Within a Large Integrated Health System.
    Pantalone KM; Wells BJ; Chagin KM; Ejzykowicz F; Yu C; Milinovich A; Bauman JM; Kattan MW; Rajpathak S; Zimmerman RS
    Diabetes Care; 2016 Sep; 39(9):1527-34. PubMed ID: 27519447
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative Effectiveness of Metformin Dosage Uptitration Versus Adding Another Antihyperglycemic Medication on Glycemic Control in Type 2 Diabetes Patients Failing Initial Metformin Monotherapy: A Retrospective Cohort Study.
    Mahabaleshwarkar R; Liu TL; Mulder H
    Popul Health Manag; 2019 Oct; 22(5):457-463. PubMed ID: 30628868
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Time to Treatment Intensification After Monotherapy Failure and Its Association With Subsequent Glycemic Control Among 93,515 Patients With Type 2 Diabetes.
    Desai U; Kirson NY; Kim J; Khunti K; King S; Trieschman E; Hellstern M; Hunt PR; Mukherjee J
    Diabetes Care; 2018 Oct; 41(10):2096-2104. PubMed ID: 30131396
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Secondary failure of glycemic control for patients adding thiazolidinedione or sulfonylurea therapy to a metformin regimen.
    Riedel AA; Heien H; Wogen J; Plauschinat CA
    Am J Manag Care; 2007 Aug; 13(8):457-63. PubMed ID: 17685826
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of Add-on Treatment to Metformin Monotherapy for Patients with Type 2 Diabetes and Suboptimal Glycemic Control: A U.S. Database Study.
    Yu S; Schwab P; Bian B; Radican L; Tunceli K
    J Manag Care Spec Pharm; 2016 Mar; 22(3):272-80. PubMed ID: 27003557
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment intensification in patients with type 2 diabetes who failed metformin monotherapy.
    Fu AZ; Qiu Y; Davies MJ; Radican L; Engel SS
    Diabetes Obes Metab; 2011 Aug; 13(8):765-9. PubMed ID: 21457427
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Determinants of Glycemic Response to Add-On Therapy with a Dipeptidyl Peptidase-4 Inhibitor: A Retrospective Cohort Study Using a United Kingdom Primary Care Database.
    Mamza J; Mehta R; Donnelly R; Idris I
    Diabetes Technol Ther; 2016 Feb; 18(2):85-92. PubMed ID: 26752504
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Achieving glycemic goal with initial versus sequential combination therapy using metformin and pioglitazone in type 2 diabetes mellitus.
    Pandya BJ; Bron M; McCall T; Yu AP; Chen KS; Mattson ME; Wu EQ
    Curr Med Res Opin; 2011 Jan; 27(1):189-95. PubMed ID: 21142610
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Change in HbA1c associated with treatment intensification among patients with type 2 diabetes and poor glycemic control.
    Fu AZ; Sheehan JJ
    Curr Med Res Opin; 2017 May; 33(5):853-858. PubMed ID: 28166431
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Distance to glycemic goal at the time of treatment intensification in patients with type 2 diabetes mellitus failing metformin monotherapy in the United States.
    Fernandes G; Sawhney B; Hannachi H; Liu J; Wang T; Fu AZ; Iglay K; McNeill A; Rajpathak S
    Curr Med Res Opin; 2020 May; 36(5):741-748. PubMed ID: 31990206
    [No Abstract]   [Full Text] [Related]  

  • 13. Effect of diacerein as an add-on to metformin in patients with type 2 diabetes mellitus and inadequate glycemic control.
    Villar MM; Martínez-Abundis E; Preciado-Márquez RO; González-Ortiz M
    Arch Endocrinol Metab; 2017; 61(2):188-192. PubMed ID: 28225996
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Foregone Opportunities? Time to Treatment Intensification Among Adults With Type 2 Diabetes and Elevated Glycated Hemoglobin on Metformin Monotherapy, 2009-2018.
    Lau D; Eurich DT; Simpson SH
    Can J Diabetes; 2022 Apr; 46(3):238-243.e4. PubMed ID: 35568424
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Level of glycemic control among US type 2 diabetes mellitus patients on dual therapy of metformin and sodium-glucose cotransporter 2 inhibitor: a retrospective database study.
    Lautsch D; Iglay K; Yang L; Bansal N; Markan R; Kathe N; Rajpathak S
    Curr Med Res Opin; 2020 Oct; 36(10):1583-1589. PubMed ID: 32866052
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Historical cohort analysis of treatment patterns for patients with type 2 diabetes initiating metformin monotherapy.
    Hazel-Fernandez L; Xu Y; Moretz C; Meah Y; Baltz J; Lian J; Kimball E; Bouchard J
    Curr Med Res Opin; 2015; 31(9):1703-16. PubMed ID: 26154837
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of a New Formulation of Nutraceuticals as an Add-On to Metformin Monotherapy for Patients with Type 2 Diabetes and Suboptimal Glycemic Control: A Randomized Controlled Trial.
    Sartore G; Ragazzi E; Antonello G; Cosma C; Lapolla A
    Nutrients; 2021 Jul; 13(7):. PubMed ID: 34371883
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patient and Provider Factors Affecting Clinical Inertia in Patients With Type 2 Diabetes on Metformin Monotherapy.
    Mahabaleshwarkar R; Gohs F; Mulder H; Wilkins N; DeSantis A; Anderson WE; Ejzykowicz F; Rajpathak S; Norton HJ
    Clin Ther; 2017 Aug; 39(8):1658-1670.e6. PubMed ID: 28689692
    [TBL] [Abstract][Full Text] [Related]  

  • 19. "Act on Threes" Paradigm for Treatment Intensification of Type 2 Diabetes in Managed Care: Results of a Randomized Controlled Study with an Educational Intervention Targeting Improved Glycemic Control.
    Bieszk N; Reynolds SL; Wei W; Davis C; Kamble P; Uribe C
    J Manag Care Spec Pharm; 2016 Sep; 22(9):1028-38. PubMed ID: 27579824
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparative study of the effects of imeglimin add-on or metformin dose escalation on glycaemic variability in subjects with type 2 diabetes treated with low-dose metformin (MEGMI-CGM study).
    Takahashi A; Nomoto H; Onishi K; Manda S; Miya A; Kameda H; Nakamura A; Atsumi T
    Diabetes Obes Metab; 2024 Aug; 26(8):3471-3474. PubMed ID: 38699794
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.